Theravance Biopharma (TBPH) Form 4/A: 15,500 at $18.50 corrected

Theravance Biopharma (TBPH) filed a Form 4/A amending an insider transaction by a director under a Rule 10b5-1 plan adopted March 14, 2024.

Rhea-AI Filing Summary

Theravance Biopharma (TBPH) filed a Form 4/A amending an insider transaction by a director under a Rule 10b5-1 plan adopted March 14, 2024. On 11/11/2025, the director sold 15,500 shares at $18.50 and 15,500 shares at $17. The filing also shows the exercise of 14,000 options at $10.15 and a same‑day sale of those 14,000 shares at $18.50. Following these transactions, beneficial ownership was 60,204 shares. The amendment corrects an earlier administrative error that had overstated one sale as 29,500 shares at $18.50.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider BROSHY ERAN

Role Director

Sold 45,000 shs ($809K)

Approx. gross sale proceeds $809K

Approx. exercise cost $142K

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	14,000	$10.15	$142K
Sale	Ordinary Shares	15,500	$18.50	$287K
Sale	Ordinary Shares	15,500	$17.00	$264K
Sale	Ordinary Shares	14,000	$18.50	$259K

Holdings After Transaction: Share Option (Right to Buy) — 107,878 contracts (Direct); Ordinary Shares — 60,204 shares (Direct)

Footnotes (3)

1. F1. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
2. F2. The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
3. F3. This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Theravance Biopharma (TBPH) report in this Form 4/A?

An amended insider transaction by a director, correcting a previously overstated sale and detailing sales executed on 11/11/2025 under a Rule 10b5-1 plan.

How many TBPH shares were sold and at what prices?

15,500 shares at $18.50 and 15,500 shares at $17 on 11/11/2025.

Were stock options involved in the TBPH insider transactions?

Yes. The director exercised 14,000 options at $10.15 and sold all 14,000 resulting shares at $18.50 the same day.

What is the corrected detail in the amendment?

A previously reported sale of 29,500 shares at $18.50 was corrected to 15,500 shares at $18.50.

What are the director’s TBPH holdings after these transactions?

Beneficial ownership was 60,204 shares following the reported transactions.

Was the trading under a preset plan?

Yes. Transactions were effected under a Rule 10b5-1 trading plan adopted on March 14, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 06:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BROSHY ERAN

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/13/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/11/2025		S	V	15,500	D	$18.5(1)	75,704	D
Ordinary Shares	11/11/2025		S	V	15,500	D	$17(1)	60,204	D
Ordinary Shares	11/11/2025		S	V	14,000	D	$18.5(2)	60,204	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$10.15	11/11/2025		M	V	14,000		(3)	04/25/2032	Ordinary Shares	14,000	$10.15	107,878	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.

2. The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.

3. This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).

Remarks:

This Form 4/A is being filed to correct an administrative error in the number of Ordinary Shares reported as sold at $18.50 on November 11, 2025. The originally reported amount of 29,500 shares in Table I, Row 1 was incorrect; the correct amount is 15,500 shares. The number of Ordinary Shares beneficially owned following the transactions has been correspondingly adjusted in all three rows of Table I.

	/s/ Brett Grimaud, Attorney-in-Fact	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.